Top Markets
Coin of the day
AgomAb Therapeutics N.V. American Depositary Shares AgomAb Therapeutics N.V. American Depositary Shares

AgomAb Therapeutics N.V. American Depositary Shares

AGMB
株式のランク #11835
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company... AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
株価
$13.26
最終同期: 2026-08-28
時価総額
$653.15M
変化(1日)
-4.17%
変化(1年)
-
BE
取引 AgomAb Therapeutics N.V. American Depositary Shares (AGMB)

カテゴリー

AgomAb Therapeutics N.V. American Depositary Shares(AGMB)の配当利回りの履歴
AgomAb Therapeutics N.V. American Depositary Shares(銘柄コード: AGMB)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
AgomAb Therapeutics N.V. American Depositary Shares(AGMB)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)